Neuroscience
In Vivo
100%
Positron Emission Tomography
82%
Parkinson's Disease
74%
Adrenergic Receptor
66%
Alpha-Synuclein
36%
Positron Emission Tomography
33%
Substantia nigra
29%
Tyrosine Hydroxylase
29%
Fluorine-18
26%
Synaptic Vesicle
25%
Neurotransmission
24%
Autoradiograph
22%
Dopaminergic
22%
Yohimbine
22%
Norepinephrine
20%
In Vitro
18%
Synuclein
16%
Medial Forebrain Bundle
16%
Domoic Acid
16%
Proteasome
16%
Stem Cell
16%
Serotonin Transporter
16%
Neuromelanin
16%
Tetrahydropyridine
16%
Cell Loss
16%
Striatum
13%
Vesicular Monoamine Transporter 2
12%
Electroconvulsive Therapy
12%
Dopaminergic Neuron
11%
Neuroprotective Agent
11%
Stereotypic Movement Disorder
11%
Radioligand
10%
Green Fluorescent Protein
10%
Dopamine Transporter
9%
Neurodegenerative Disorder
8%
Neurodegeneration
8%
Hypothalamus
8%
Levetiracetam
8%
Beta1 Integrin
8%
Iodine-123
7%
Single-Photon Emission Computed Tomography
7%
Adeno-Associated Virus
6%
Antidepressant
5%
Synapse
5%
Eicosanoid Receptor
5%
Tremor
5%
Pons
5%
Ubiquitin
5%
Face
5%
Dementia with Lewy Bodies
5%
Pharmacology, Toxicology and Pharmaceutical Science
Parkinson's Disease
55%
Carbon 11
22%
Alpha Synuclein
20%
Tracer
19%
Disease
18%
Dopamine Receptor Stimulating Agent
18%
Sprague Dawley Rat
16%
Synuclein
16%
Electric Shock
16%
Adrenergic Receptor
16%
Minipig
16%
1,2,3,6 Tetrahydro 1 Methyl 4 Phenylpyridine
16%
Lactacystin
13%
Fluorine 18
11%
Biological Marker
10%
Autoradiography
7%
Clinical Trial
6%
Degenerative Disease
5%
Dihydrotetrabenazine
5%
Mouse
5%
Pharmacokinetics
5%
Diffuse Lewy Body Disease
5%
Keyphrases
Human α-synuclein
16%
Glial Activation
16%
Cell Loss
16%
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
16%
Minipig
16%
Striatal
16%
Partial Recovery
16%
Arterial Blood Sampling
16%
18F-DOPA
7%
Positron Emission Tomography
7%
Recombinant Adeno-associated Virus (rAAV)
6%
VMAT2
6%
Dihydrotetrabenazine
5%